SELLAS Life Sciences Group, Inc. Operating Income
SELLAS Life Sciences Group, Inc. (SLS) reported Operating Income of -$10.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$10.63M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$9.25M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$8.26M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$7.08M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for fiscal 2025 was -$28.27M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for fiscal 2024 was -$31.51M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for fiscal 2023 was -$37.87M.
- SELLAS Life Sciences Group, Inc. operating income (loss) for fiscal 2022 was -$41.95M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed | Operating Income (Loss) 102 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.63M 10-Q · filed 2026-08-11 | -$19.88M 10-Q · filed 2026-08-11 | -$28.14M derived: sum of 3 quarters · filed 2026-08-11 | -$35.22M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | -$9.25M 10-Q · filed 2026-05-12 | -$17.51M derived: sum of 2 quarters · filed 2026-05-12 | -$24.59M derived: sum of 3 quarters · filed 2026-05-12 | -$31.46M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | -$8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$15.34M derived: sum of 2 quarters · filed 2026-03-19 | -$22.21M derived: sum of 3 quarters · filed 2026-08-11 | -$28.27M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | -$7.08M 10-Q · filed 2025-11-12 | -$13.96M derived: sum of 2 quarters · filed 2026-08-11 | -$20.02M 10-Q · filed 2025-11-12 | -$26.94M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | -$6.87M 10-Q · filed 2026-08-11 | -$12.94M 10-Q · filed 2026-08-11 | -$19.85M derived: sum of 3 quarters · filed 2026-08-11 | -$27.18M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-03-31 | -$6.06M 10-Q · filed 2026-05-12 | -$12.98M derived: sum of 2 quarters · filed 2026-05-12 | -$20.31M derived: sum of 3 quarters · filed 2026-05-12 | -$27.93M derived: sum of 4 quarters · filed 2026-05-12 | |||||
| 2024-12-31 | -$6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$14.25M derived: sum of 2 quarters · filed 2026-03-19 | -$21.87M derived: sum of 3 quarters · filed 2026-03-19 | -$31.51M 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | -$7.33M 10-Q · filed 2025-11-12 | -$14.95M derived: sum of 2 quarters · filed 2025-11-12 | -$24.59M 10-Q · filed 2025-11-12 | -$32.77M derived: sum of 4 quarters · filed 2025-11-12 | |||||
| 2024-06-30 | -$7.62M 10-Q · filed 2025-08-12 | -$17.27M 10-Q · filed 2025-08-12 | -$25.44M derived: sum of 3 quarters · filed 2025-08-12 | -$34.80M derived: sum of 4 quarters · filed 2025-08-12 | |||||
| 2024-03-31 | -$9.64M 10-Q · filed 2025-05-13 | -$17.82M derived: sum of 2 quarters · filed 2025-05-13 | -$27.18M derived: sum of 3 quarters · filed 2025-05-13 | -$36.23M derived: sum of 4 quarters · filed 2025-05-13 | |||||
| 2023-12-31 | -$8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$17.54M derived: sum of 2 quarters · filed 2025-03-20 | -$26.59M derived: sum of 3 quarters · filed 2025-03-20 | -$37.87M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | -$9.36M 10-Q · filed 2024-11-13 | -$18.41M derived: sum of 2 quarters · filed 2024-11-13 | -$29.69M 10-Q · filed 2024-11-13 | -$39.14M derived: sum of 4 quarters · filed 2024-11-13 | |||||
| 2023-06-30 | -$9.05M 10-Q · filed 2024-08-13 | -$20.33M 10-Q · filed 2024-08-13 | -$29.78M derived: sum of 3 quarters · filed 2024-08-13 | -$36.92M derived: sum of 4 quarters · filed 2024-08-13 | |||||
| 2023-03-31 | -$11.28M 10-Q · filed 2024-05-14 | -$20.73M derived: sum of 2 quarters · filed 2024-05-14 | -$27.87M derived: sum of 3 quarters · filed 2024-05-14 | -$36.50M derived: sum of 4 quarters · filed 2024-05-14 | |||||
| 2022-12-31 | -$9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$16.59M derived: sum of 2 quarters · filed 2024-03-28 | -$25.21M derived: sum of 3 quarters · filed 2024-03-28 | -$41.95M 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | -$7.15M 10-Q · filed 2023-11-09 | -$15.77M derived: sum of 2 quarters · filed 2023-11-09 | -$32.50M 10-Q · filed 2023-11-09 | -$44.12M derived: sum of 4 quarters · filed 2023-11-09 | |||||
| 2022-06-30 | -$8.62M 10-Q · filed 2023-08-10 | -$25.36M 10-Q · filed 2023-08-10 | -$36.98M derived: sum of 3 quarters · filed 2023-08-10 | -$43.95M derived: sum of 4 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | -$16.73M 10-Q · filed 2023-05-11 | -$28.35M derived: sum of 2 quarters · filed 2023-05-11 | -$35.33M derived: sum of 3 quarters · filed 2023-05-11 | -$39.78M derived: sum of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | -$11.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$18.60M derived: sum of 2 quarters · filed 2023-03-16 | -$23.05M derived: sum of 3 quarters · filed 2023-03-16 | -$25.29M 10-K · filed 2023-03-16 | |||||
| 2021-09-30 | -$6.98M 10-Q · filed 2022-11-14 | -$11.43M derived: sum of 2 quarters · filed 2022-11-14 | -$13.68M 10-Q · filed 2022-11-14 | -$17.83M derived: sum of 4 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | -$4.45M 10-Q · filed 2022-08-11 | -$6.70M 10-Q · filed 2022-08-11 | -$10.86M derived: sum of 3 quarters · filed 2022-08-11 | -$15.35M derived: sum of 4 quarters · filed 2022-08-11 | |||||
| 2021-03-31 | -$2.25M 10-Q · filed 2022-05-12 | -$6.40M derived: sum of 2 quarters · filed 2022-05-12 | -$10.90M derived: sum of 3 quarters · filed 2022-05-12 | -$15.16M derived: sum of 4 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | -$4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$8.65M derived: sum of 2 quarters · filed 2022-03-31 | -$12.92M derived: sum of 3 quarters · filed 2022-03-31 | -$16.98M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | -$4.49M 10-Q · filed 2021-11-12 | -$8.76M derived: sum of 2 quarters · filed 2021-11-12 | -$12.82M 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | -$4.27M 10-Q · filed 2021-08-12 | -$8.33M 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | -$4.06M 10-Q · filed 2021-05-13 | ||||||||
| 2019-12-31 | -$20.04M 10-K · filed 2021-03-23 | ||||||||
| 2017-12-31 | -$8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | -$13.04M derived: sum of 2 quarters · filed 2018-04-13 | -$17.95M derived: sum of 3 quarters · filed 2018-04-13 | -$23.04M 10-K · filed 2018-04-13 | |||||
| 2017-09-30 | -$4.46M 10-Q · filed 2017-11-09 | -$9.37M derived: sum of 2 quarters · filed 2017-11-09 | -$14.46M 10-Q · filed 2017-11-09 | -$5.72M derived: sum of 4 quarters · filed 2018-04-13 | |||||
| 2017-06-30 | -$4.91M 10-Q · filed 2017-08-14 | -$10.00M 10-Q · filed 2017-08-14 | -$1.25M derived: sum of 3 quarters · filed 2018-04-13 | -$7.73M derived: sum of 4 quarters · filed 2018-04-13 | |||||
| 2017-03-31 | -$5.09M 10-Q · filed 2017-05-10 | $3.66M derived: sum of 2 quarters · filed 2018-04-13 | -$2.82M derived: sum of 3 quarters · filed 2018-04-13 | -$12.11M derived: sum of 4 quarters · filed 2018-04-13 | |||||
| 2016-12-31 | $8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | $2.27M derived: sum of 2 quarters · filed 2018-04-13 | -$7.02M derived: sum of 3 quarters · filed 2018-04-13 | -$15.99M 10-K · filed 2018-04-13 | -$31.87M 10-K · filed 2017-03-15 | ||||
| 2016-09-30 | -$6.47M 10-Q · filed 2017-11-09 | -$15.76M derived: sum of 2 quarters · filed 2017-11-09 | -$24.73M 10-Q · filed 2017-11-09 | -$32.32M derived: sum of 4 quarters · filed 2017-11-09 | |||||
| 2016-06-30 | -$9.29M 10-Q · filed 2017-08-14 | -$18.26M 10-Q · filed 2017-08-14 | -$25.85M derived: sum of 3 quarters · filed 2017-08-14 | -$34.48M derived: sum of 4 quarters · filed 2017-08-14 | |||||
| 2016-03-31 | -$8.97M 10-Q · filed 2017-05-10 | -$16.56M derived: sum of 2 quarters · filed 2017-05-10 | -$25.19M derived: sum of 3 quarters · filed 2017-05-10 | -$34.27M derived: sum of 4 quarters · filed 2017-05-10 | |||||
| 2015-12-31 | -$7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$16.22M derived: sum of 2 quarters · filed 2017-03-15 | -$25.31M derived: sum of 3 quarters · filed 2017-03-15 | -$34.22M 10-K · filed 2017-03-15 | |||||
| 2015-09-30 | -$8.63M 10-Q · filed 2016-11-09 | -$17.72M derived: sum of 2 quarters · filed 2016-11-09 | -$26.63M 10-Q · filed 2016-11-09 | -$36.32M derived: sum of 4 quarters · filed 2017-03-15 | |||||
| 2015-06-30 | -$9.08M 10-Q · filed 2016-08-09 | -$11.27M 10-Q · filed 2015-08-06 | -$18.00M 10-Q · filed 2016-08-09 | -$22.39M 10-Q · filed 2015-08-06 | -$27.69M derived: sum of 3 quarters · filed 2017-03-15 | -$38.26M derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-03-31 | -$8.91M 10-Q · filed 2016-05-10 | -$11.13M 10-Q · filed 2015-05-07 | -$18.61M derived: sum of 2 quarters · filed 2017-03-15 | -$29.17M derived: sum of 3 quarters · filed 2017-03-15 | -$44.95M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | -$9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$20.26M derived: sum of 2 quarters · filed 2017-03-15 | -$36.04M derived: sum of 3 quarters · filed 2017-03-15 | -$43.90M 10-K · filed 2017-03-15 | -$52.22M 10-K · filed 2015-03-05 | ||||
| 2014-09-30 | -$10.57M 10-Q · filed 2015-11-09 | -$13.21M 10-Q · filed 2014-11-05 | -$26.35M derived: sum of 2 quarters · filed 2015-11-09 | -$34.21M 10-Q · filed 2015-11-09 | -$40.84M 10-Q · filed 2014-11-05 | -$45.20M derived: sum of 4 quarters · filed 2016-04-15 | |||
| 2014-06-30 | -$15.78M 10-Q · filed 2015-08-06 | -$27.63M 10-Q · filed 2015-08-06 | -$34.63M derived: sum of 3 quarters · filed 2016-04-15 | -$41.52M derived: sum of 4 quarters · filed 2016-04-15 | |||||
| 2014-03-31 | -$11.85M 10-Q · filed 2015-05-07 | -$18.85M derived: sum of 2 quarters · filed 2016-04-15 | -$25.74M derived: sum of 3 quarters · filed 2016-04-15 | -$33.73M derived: sum of 4 quarters · filed 2016-04-15 | |||||
| 2013-12-31 | -$7.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-04-15 | -$13.89M derived: sum of 2 quarters · filed 2016-04-15 | -$21.88M derived: sum of 3 quarters · filed 2016-04-15 | -$28.49M 10-K/A · filed 2016-04-15 | -$33.84M 10-K · filed 2014-03-17 | ||||
| 2013-09-30 | -$6.89M 10-Q · filed 2014-11-05 | -$14.88M derived: sum of 2 quarters · filed 2014-11-05 | -$21.49M 10-Q · filed 2014-11-05 | -$27.07M derived: sum of 4 quarters · filed 2015-12-04 | |||||
| 2013-06-30 | -$7.99M 10-Q · filed 2014-08-11 | -$14.60M 10-Q · filed 2014-08-11 | -$20.18M derived: sum of 3 quarters · filed 2015-12-04 | -$25.70M derived: sum of 4 quarters · filed 2015-12-04 | |||||
| 2013-03-31 | -$6.61M 10-Q · filed 2014-05-06 | -$12.19M derived: sum of 2 quarters · filed 2015-12-04 | -$17.72M derived: sum of 3 quarters · filed 2015-12-04 | ||||||
| 2012-12-31 | -$5.58M derived: 8-K 12 month − 10-Q/A 9 month · filed 2015-12-04 | -$11.11M derived: sum of 2 quarters · filed 2015-12-04 | -$21.20M 8-K · filed 2015-12-04 | ||||||
| 2012-09-30 | -$5.53M 10-Q/A · filed 2013-11-07 | -$15.62M 10-Q/A · filed 2013-11-07 | |||||||
| 2011-12-31 | -$12.49M 10-K · filed 2014-03-17 | ||||||||
| 2011-06-30 | -$4.62M 10-Q · filed 2011-08-15 | -$9.90M 10-Q · filed 2011-08-15 | -$80.07M 10-Q · filed 2011-08-15 | ||||||
| 2010-06-30 | -$4.75M 10-Q · filed 2011-08-15 | -$9.21M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |